Dominari (DOMH) Competitors $4.74 -0.52 (-9.89%) As of 05/21/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DOMH vs. XOMA, VNDA, CDXS, LXRX, SGMO, ACHV, AGEN, IRWD, FBIO, and CRISShould you be buying Dominari stock or one of its competitors? The main competitors of Dominari include XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Lexicon Pharmaceuticals (LXRX), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), Agenus (AGEN), Ironwood Pharmaceuticals (IRWD), Fortress Biotech (FBIO), and Curis (CRIS). These companies are all part of the "biotechnology" industry. Dominari vs. XOMA Vanda Pharmaceuticals Codexis Lexicon Pharmaceuticals Sangamo Therapeutics Achieve Life Sciences Agenus Ironwood Pharmaceuticals Fortress Biotech Curis Dominari (NASDAQ:DOMH) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Does the media refer more to DOMH or XOMA? In the previous week, XOMA had 11 more articles in the media than Dominari. MarketBeat recorded 12 mentions for XOMA and 1 mentions for Dominari. XOMA's average media sentiment score of 0.81 beat Dominari's score of 0.00 indicating that XOMA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dominari 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral XOMA 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in DOMH or XOMA? 42.5% of Dominari shares are owned by institutional investors. Comparatively, 95.9% of XOMA shares are owned by institutional investors. 33.0% of Dominari shares are owned by company insiders. Comparatively, 7.2% of XOMA shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is DOMH or XOMA more profitable? XOMA has a net margin of -151.34% compared to Dominari's net margin of -180.22%. XOMA's return on equity of -24.95% beat Dominari's return on equity.Company Net Margins Return on Equity Return on Assets Dominari-180.22% -32.89% -29.47% XOMA -151.34%-24.95%-9.64% Which has stronger valuation and earnings, DOMH or XOMA? Dominari has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDominari$24.89M2.79-$22.88M-$4.50-1.05XOMA$13.05M23.04-$40.83M-$1.15-21.84 Do analysts recommend DOMH or XOMA? XOMA has a consensus price target of $69.50, suggesting a potential upside of 176.67%. Given XOMA's stronger consensus rating and higher probable upside, analysts clearly believe XOMA is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00XOMA 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, DOMH or XOMA? Dominari has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, XOMA has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Does the MarketBeat Community prefer DOMH or XOMA? XOMA received 442 more outperform votes than Dominari when rated by MarketBeat users. CompanyUnderperformOutperformDominariN/AN/AXOMAOutperform Votes44265.58% Underperform Votes23234.42% SummaryXOMA beats Dominari on 13 of the 17 factors compared between the two stocks. Get Dominari News Delivered to You Automatically Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DOMH vs. The Competition Export to ExcelMetricDominariSecurity brokers & dealers IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.41M$32.31B$5.36B$8.39BDividend YieldN/A2.51%5.22%4.10%P/E Ratio-1.2215.6026.5919.72Price / Sales2.795.96391.61116.20Price / CashN/A22.5338.2534.62Price / Book0.482.916.794.51Net Income-$22.88M$1.49B$3.23B$248.18M7 Day Performance-18.56%-1.23%4.03%1.14%1 Month Performance16.46%15.63%12.22%15.07%1 Year Performance121.50%31.24%16.76%6.59% Dominari Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DOMHDominari0.8663 of 5 stars$4.74-9.9%N/A+121.5%$69.41M$24.89M-1.224XOMAXOMA4.0917 of 5 stars$27.48+1.8%$69.50+152.9%-3.0%$328.47M$10.22M-7.9010News CoverageInsider TradeAnalyst RevisionGap UpVNDAVanda Pharmaceuticals4.3723 of 5 stars$4.31+3.6%$16.50+282.8%-15.5%$254.01M$201.35M-13.47290CDXSCodexis3.3106 of 5 stars$2.43-1.6%$8.00+229.2%-33.3%$204.63M$59.35M-2.79250Positive NewsAnalyst RevisionGap UpLXRXLexicon Pharmaceuticals3.1928 of 5 stars$0.56+3.8%$3.67+559.7%-63.3%$200.92M$31.08M-0.74140SGMOSangamo Therapeutics2.0417 of 5 stars$0.50+6.1%$4.50+802.7%-16.3%$116.23M$63.76M-0.66480Analyst RevisionACHVAchieve Life Sciences1.8853 of 5 stars$3.31+7.5%$14.33+333.0%-39.0%$114.81MN/A-2.9320High Trading VolumeAGENAgenus3.968 of 5 stars$3.79+8.9%$9.00+137.5%-67.1%$103.91M$99.52M-0.34440Analyst RevisionGap DownIRWDIronwood Pharmaceuticals4.528 of 5 stars$0.61+7.4%$4.78+681.7%-91.3%$99.02M$317.68M-20.40220Positive NewsFBIOFortress Biotech1.6379 of 5 stars$1.76-2.8%$21.00+1,093.2%-14.1%$52.04M$57.68M-0.58170CRISCuris3.0391 of 5 stars$2.08+2.5%$17.00+717.3%-82.0%$21.76M$11.20M-0.2760Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies XOMA Competitors Vanda Pharmaceuticals Competitors Codexis Competitors Lexicon Pharmaceuticals Competitors Sangamo Therapeutics Competitors Achieve Life Sciences Competitors Agenus Competitors Ironwood Pharmaceuticals Competitors Fortress Biotech Competitors Curis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DOMH) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dominari Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dominari With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DOMH Stock Free DOMH Stock Alerts